In response to a request to consolidate an apparently mounting group of lawsuits over the chemotherapy drug Taxotere, the New Jersey state court system has asked the bar for feedback on the possible establishment of multi-county litigation.

The litigation involves, as of last month, 353 pending cases against drugmaker Sanofi-Aventis claiming products liability and fraud, and alleging that Taxotere caused permanent hair loss. A notice to the bar dated April 11 and made public the following week was issued by Acting Administrative Director of the Court Glenn A. Grant.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]